Amphastar Pharmaceuticals (AMPH) Cash from Financing Activities (2013 - 2026)

Amphastar Pharmaceuticals' Cash from Financing Activities history runs 14 years deep, the most recent figure standing at -$30.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 108.28% year-over-year to -$30.2 million; the TTM figure through Mar 2026 stood at -$83.1 million (down 1.53% YoY), while the FY2025 annual figure was -$67.4 million, up 16.71% from the prior year.
• Cash from Financing Activities was -$30.2 million for Q1 2026 at Amphastar Pharmaceuticals, down from -$18.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $428.1 million in Q2 2023 to a low of -$47.1 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $14.7 million across 5 years, with a median of -$13.9 million in 2022.
• Biggest YoY gain for Cash from Financing Activities was 43169.52% in 2023; the steepest drop was 391.48% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$16.2 million in 2022, then sank by 191.32% to -$47.1 million in 2023, then rose by 28.12% to -$33.8 million in 2024, then jumped by 45.71% to -$18.4 million in 2025, then sank by 64.41% to -$30.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$30.2 million (Q1 2026), -$18.4 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.